These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Molecular Pathogenesis, Immunopathogenesis and Novel Therapeutic Strategy Against COVID-19. Chatterjee SK; Saha S; Munoz MNM Front Mol Biosci; 2020; 7():196. PubMed ID: 32850977 [TBL] [Abstract][Full Text] [Related]
3. A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes. Funk CD; Ardakani A Front Pharmacol; 2020; 11():1214. PubMed ID: 32848802 [TBL] [Abstract][Full Text] [Related]
4. Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. Hon KL; Leung KKY; Leung AK; Qian SY; Chan VP; Ip P; Wong IC Drugs Context; 2020; 9():. PubMed ID: 32655654 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases. Tsuchiya A; Takeuchi S; Iwasawa T; Kumagai M; Sato T; Motegi S; Ishii Y; Koseki Y; Tomiyoshi K; Natsui K; Takeda N; Yoshida Y; Yamazaki F; Kojima Y; Watanabe Y; Kimura N; Tominaga K; Kamimura H; Takamura M; Terai S Inflamm Regen; 2020; 40():14. PubMed ID: 32582401 [TBL] [Abstract][Full Text] [Related]
6. Hydrogen: A Potential New Adjuvant Therapy for COVID-19 Patients. Yang F; Yue R; Luo X; Liu R; Huang X Front Pharmacol; 2020; 11():543718. PubMed ID: 33178011 [TBL] [Abstract][Full Text] [Related]
7. COVID-19 antiviral pills raise hopes for curbing pandemic. Harrison C Nat Biotechnol; 2021 Nov; ():. PubMed ID: 34824387 [No Abstract] [Full Text] [Related]
8. Covid-19: Gothic sanctuary gives hope for the future. Shepherd A BMJ; 2021 Jan; 372():n155. PubMed ID: 33472832 [No Abstract] [Full Text] [Related]
9. Recent Advances in Molecular diagnosis curbing the COVID-19. Aziz H; Fatima S; Iqbal H; Faheem M Int J Infect Dis; 2020 Aug; 97():322-325. PubMed ID: 32522596 [TBL] [Abstract][Full Text] [Related]
10. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations. Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993 [TBL] [Abstract][Full Text] [Related]
11. Management of the patient with allergic and immunological disorders in the pandemic COVID-19 era. Patella V; Delfino G; Florio G; Spadaro G; Chieco Bianchi F; Senna G; Di Gioacchino M Clin Mol Allergy; 2020; 18():18. PubMed ID: 33020697 [TBL] [Abstract][Full Text] [Related]
12. ACE2 expression in allergic airway disease may decrease the risk and severity of COVID-19. Chhapola Shukla S Eur Arch Otorhinolaryngol; 2021 Jul; 278(7):2637-2640. PubMed ID: 33025046 [TBL] [Abstract][Full Text] [Related]
13. Reposition of montelukast either alone or in combination with levocetirizine against SARS-CoV-2. Bhattacharyya D Med Hypotheses; 2020 Nov; 144():110046. PubMed ID: 33254480 [TBL] [Abstract][Full Text] [Related]
14. A possible effect of montelukast on neurological aging examined by the use of register data. Grinde B; Schirmer H; Eggen AE; Aigner L; Engdahl B Int J Clin Pharm; 2021 Jun; 43(3):541-548. PubMed ID: 33034810 [TBL] [Abstract][Full Text] [Related]
15. The Human Respiratory System and its Microbiome at a Glimpse. Santacroce L; Charitos IA; Ballini A; Inchingolo F; Luperto P; De Nitto E; Topi S Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33019595 [TBL] [Abstract][Full Text] [Related]
16. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic. Aigner L; Pietrantonio F; Bessa de Sousa DM; Michael J; Schuster D; Reitsamer HA; Zerbe H; Studnicka M Front Mol Biosci; 2020; 7():610132. PubMed ID: 33392263 [TBL] [Abstract][Full Text] [Related]